The functional impact of CCL17 on cholangiocarcinoma cells.
RNA-seq (gene expression) · human · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- CholangiocarcinomaThis series is part of our curated briefing on it.
- Samples
- 12 samples: 4 × Control vs 4 × CCL17+C-021 vs 4 × CCL17Groups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE269158_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1120426 and SRA study SRP511986. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 3 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8307198 Control-rep1 Control
- GSM8307199 Control-rep2 Control
- GSM8307200 Control-rep3 Control
- GSM8307201 Control-rep4 Control
- GSM8307202 CCL17+C-021-rep1 CCL17+C-021
- GSM8307203 CCL17+C-021-rep2 CCL17+C-021
- GSM8307204 CCL17+C-021-rep3 CCL17+C-021
- GSM8307205 CCL17+C-021-rep4 CCL17+C-021
- GSM8307206 CCL17-rep1 CCL17
- GSM8307207 CCL17-rep2 CCL17
- GSM8307208 CCL17-rep3 CCL17
- GSM8307209 CCL17-rep4 CCL17
- GSE262746 Nab-paclitaxel induces DNA damage and inhibits M2 polarization of macrophages to achieve radiosensitization of cholangiocarcinoma cells. 12 samples same disease briefing · shares cholangiocarcinoma
- GSE269494 Surufatinib increases cholangiocarcinoma cells radiosensitivity by anti-tumor proliferation and inhibition of macrophage M2 polarization 12 samples same disease briefing · shares cholangiocarcinoma
- GSE213452 Gene expression profile at single cell level of cells from cholangiocarcinoma(CCA) and adjacent tissues. 11 samples same disease briefing · shares cholangiocarcinoma
- GSE231854 The heterogeneity analysis of hepatocellular carcinoma and combined hepatocellular cholangiocarcinoma 81 samples same disease briefing · shares cholangiocarcinoma
- GSE269055 Function of primary human mast cells (huMCs) in cholangiocarcinoma tissue. 9 samples same disease briefing · shares cholangiocarcinoma
- GSE273905 Targeting Cancer Associated Fibroblasts/Tumor Cells Cross-Talk Inhibits Intrahepatic Cholangiocarcinoma Progression 9 samples same disease briefing · shares cholangiocarcinoma
- GSE317889 Combined DNA and RNA profiling refines prognostic stratification independent of therapeutic actionability in cholangiocarcinoma 62 samples same disease briefing · shares cholangiocarcinoma
- GSE308455 Functional characterization of BAP1 mutations in genome edited cholangiocarcinoma organoids: role in cell death and drug responses 6 samples same disease briefing · shares cholangiocarcinoma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.